Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.
Last trade$245.09
Day change+$0.21 (+0.09%)
Day range$239.68 – $247.14
Volume396,952
Market cap$14.50B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$14.5B
Price / earnings
—
Price / book
20.21×
Price / sales
21×
EV / sales
20.86×
EV / EBITDA
-107.17×
Profitability
Earnings per share
-$2.87
Return on assets
-17.33%
Return on equity
-23.67%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0.09×
Current ratio
4.57×
Quick ratio
4.09×
Cash ratio
1.28×
Cash flow
Price / cash flow
303.84×
Price / free cash flow
402.45×
Free cash flow
$36.02M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for GKOS, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$211.03M
$185.61M
$150.57M
$143.12M
$133.54M
$124.12M
$106.66M
$105.5M
Cost of revenue
$31.16M
$34.02M
$33.34M
$144.64M
$28.83M
$26.9M
$24.32M
$28.64M
Gross profit
$179.87M
$151.59M
$117.23M
-$1.52M
$104.71M
$97.22M
$82.35M
$76.86M
Selling, general and administrative
$130.94M
$116.06M
$92.94M
$94.7M
$83M
$83.38M
$70.67M
$69M
Research and development
$48.1M
$52.8M
$44.15M
$43.65M
$38.07M
$36.54M
$32.35M
$36.53M
Total operating expenses
$179.04M
$168.86M
$137.09M
$138.35M
$121.07M
$119.91M
$103.03M
$105.53M
Operating income
$828K
-$17.27M
-$19.86M
-$139.87M
-$16.37M
-$22.69M
-$20.68M
-$28.67M
Interest expense
-$1.09M
-$1.46M
-$1.13M
-$1.15M
-$1.18M
-$1.15M
-$1.16M
-$1.57M
Income before taxes
$2.32M
-$17.72M
-$19.3M
-$139.82M
-$16M
-$19.41M
-$17.82M
-$33.69M
Income taxes
$303K
$656K
$484K
-$6.16M
$234K
$248K
$326K
-$114K
Net income
$2.02M
-$18.38M
-$19.78M
-$133.66M
-$16.23M
-$19.66M
-$18.15M
-$33.58M
Net income attributable to common shareholders
$2.02M
-$18.38M
-$19.78M
-$133.66M
-$16.23M
-$19.66M
-$18.15M
-$33.58M
EBITDA
$9.78M
-$8.4M
-$8.06M
-$127.7M
-$7.23M
-$14.12M
-$12.45M
-$19.93M
Basic earnings per share
$0.03
-$0.31
-$0.34
-$2.32
-$0.28
-$0.34
-$0.32
-$0.60
Diluted earnings per share
$0.03
-$0.31
-$0.34
-$2.32
-$0.28
-$0.34
-$0.32
-$0.60
Recent news
Company coverage with links to the original publishers.
GE HealthCare Technologies (GEHC) is well-positioned for growth with a record $23.7 billion backlog (up 12%), strong Pharmaceutical Diagnostics revenue growth, and raised 2026 guidance. However, persistent component inflation, tariff uncertainty, and China's fragile recovery pose risks to margin expansion.
Doximity announced an expansion of its AI-powered clinical tools partnership with NewYork-Presbyterian, Columbia University, and Weill Cornell Medicine. The collaboration includes Doximity Ask (clinical decision support integrated with Epic EHR) and Doximity Scribe (patient documentation and dictation). The company also launched DoseCheck, a safety feature reducing dosing errors by over 99%. Despite the positive developments, DOCS stock has declined 24.7% year-to-date.
Koninklijke Philips reported strong equipment order intake growth of 8% with Diagnosis & Treatment orders surging nearly 20%, and Personal Health sales rising 8%. However, ultrasound manufacturing delays, China's pricing pressure from centralized procurement, and inflation concerns pose significant risks to profitability and growth trajectory. The company maintains a Zacks Rank #3 (Hold) rating.
GE HealthCare Technologies announced the formation of the MAGNUS Neuro Alliance, a collaborative research network using its head-only 3.0T MR system to advance neuroscience research. The alliance will unite leading institutions for multi-site trials and research focused on developing MRI-based biomarkers for neurological diseases. GEHC stock declined 2.2% following the announcement, though the initiative could strengthen the company's position in advanced imaging and create long-term growth opportunities.
AngioDynamics (ANGO) is gaining momentum from strong NanoKnife platform performance, with revenues surging 29% to $8.3 million in fiscal Q1 2027, driven by rising prostate procedure volumes and expanded regulatory approvals. The company's Med Tech segment continues robust growth with 13.2% year-over-year revenue increase, and management expects 12%-15% Med Tech revenue growth in fiscal 2027. However, tariffs and inflation remain headwinds despite recent tariff refunds improving margins.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.